董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Breen | 男 | Chief Executive Officer, Director and Executive Chairman of the Board | 63 | 172.76万美元 | 1.29 | 2026-06-30 |
| David C. Mun Gavin | 男 | Director | 79 | 6.96万美元 | 0.13 | 2026-06-30 |
| Hilary Kramer | 女 | Director | 62 | 7.57万美元 | 0.13 | 2026-06-30 |
| Charles J. Casamento | 男 | Director | 80 | 13.19万美元 | 0.32 | 2026-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Breen | 男 | Chief Executive Officer, Director and Executive Chairman of the Board | 63 | 172.76万美元 | 1.29 | 2026-06-30 |
| Alan Urban | 男 | Chief Financial Officer and Secretary | 57 | 73.93万美元 | 0.43 | 2026-06-30 |
董事简历
中英对照 | 中文 | 英文- Michael Breen
-
Michael Breen自2017年3月起担任公司董事。Breen先生是一名英国合格的律师，曾担任Bank Insinger de Beaufort N.V.体育和娱乐部门的常务董事，这是一家财富管理机构，也是法国巴黎银行集团（BNP Paribas Group）的一部分，后者是世界上最大的银行之一。他曾担任Clyde&Co律师事务所的股权合伙人，在那里他专注于体育和娱乐法的所有方面。Breen先生还在基于事件的娱乐方面拥有丰富的经验，曾负责与世界著名的英国音乐奖（Brit Awards）相关的法律文件。Breen先生拥有威尔士大学学院（University College of Wales，Aberystwyth）法学荣誉法学学士学位。
Michael Breen was appointed to Gt Biopharma, Inc.'s Board of Directors on January 13, 2021, was appointed Executive Chairman of the Board of Directors on November 8, 2021 and was appointed as Gt Biopharma, Inc.'s Chief Executive Officer on April 29, 2025 for a two year term. Mr. Breen served as Gt Biopharma, Inc.'s Interim Chief Executive Officer from March 2, 2022 to April 29, 2025. Prior to joining Gt Biopharma, Inc.'s company, Mr. Breen served as a senior partner in the global law firm of Clyde & Co., specializing in all aspects of corporate law, including mergers and acquisitions and fund management regulatory issues, which included advising clients in the biotechnology and health sciences sectors. Prior to joining Clyde & Co., Mr. Breen served as a senior partner and managing partner in the London law firm of Edward Lewis. Prior to his time at Edward Lewis, he was also a partner at Robert Gore & Company. Between 2002 and 2005, Mr. Breen was managing director and a shareholder of the Sports and Entertainment Division of Insinger de Beaufort Bank, a Dutch private banking, asset management and trust group listed on the Luxembourg stock exchange. From 2001 to 2007 Mr. Breen also served as a non executive director and co owner of Damon Hill Holdings Limited, a multi franchise motor dealer group. Mr. Breen also serves as a director of a Cayman Islands fund, Bristol Investment Fund, Limited. Mr. Breen is also a non executive director and co owner of Colorsport Images Limited, a sports photographic agency and library. Mr. Breen is a U.K. qualified solicitor/attorney who holds an Honours LL.B. degree in law from the University College of Wales, Aberystwyth and qualified as a solicitor of the Supreme Court of Judicature of England and Wales in 1988. Mr. Breen is a former member of the International Bar Association, British Association for Sport and the Law, Law Society of England and Wales, and Holborn Law Society. - Michael Breen自2017年3月起担任公司董事。Breen先生是一名英国合格的律师，曾担任Bank Insinger de Beaufort N.V.体育和娱乐部门的常务董事，这是一家财富管理机构，也是法国巴黎银行集团（BNP Paribas Group）的一部分，后者是世界上最大的银行之一。他曾担任Clyde&Co律师事务所的股权合伙人，在那里他专注于体育和娱乐法的所有方面。Breen先生还在基于事件的娱乐方面拥有丰富的经验，曾负责与世界著名的英国音乐奖（Brit Awards）相关的法律文件。Breen先生拥有威尔士大学学院（University College of Wales，Aberystwyth）法学荣誉法学学士学位。
- Michael Breen was appointed to Gt Biopharma, Inc.'s Board of Directors on January 13, 2021, was appointed Executive Chairman of the Board of Directors on November 8, 2021 and was appointed as Gt Biopharma, Inc.'s Chief Executive Officer on April 29, 2025 for a two year term. Mr. Breen served as Gt Biopharma, Inc.'s Interim Chief Executive Officer from March 2, 2022 to April 29, 2025. Prior to joining Gt Biopharma, Inc.'s company, Mr. Breen served as a senior partner in the global law firm of Clyde & Co., specializing in all aspects of corporate law, including mergers and acquisitions and fund management regulatory issues, which included advising clients in the biotechnology and health sciences sectors. Prior to joining Clyde & Co., Mr. Breen served as a senior partner and managing partner in the London law firm of Edward Lewis. Prior to his time at Edward Lewis, he was also a partner at Robert Gore & Company. Between 2002 and 2005, Mr. Breen was managing director and a shareholder of the Sports and Entertainment Division of Insinger de Beaufort Bank, a Dutch private banking, asset management and trust group listed on the Luxembourg stock exchange. From 2001 to 2007 Mr. Breen also served as a non executive director and co owner of Damon Hill Holdings Limited, a multi franchise motor dealer group. Mr. Breen also serves as a director of a Cayman Islands fund, Bristol Investment Fund, Limited. Mr. Breen is also a non executive director and co owner of Colorsport Images Limited, a sports photographic agency and library. Mr. Breen is a U.K. qualified solicitor/attorney who holds an Honours LL.B. degree in law from the University College of Wales, Aberystwyth and qualified as a solicitor of the Supreme Court of Judicature of England and Wales in 1988. Mr. Breen is a former member of the International Bar Association, British Association for Sport and the Law, Law Society of England and Wales, and Holborn Law Society.
- David C. Mun Gavin
-
David C. Mun Gavin于2025年6月10日被任命为GT Biopharma, Inc.董事会成员。Mun Gavin先生自2018年10月起担任五重奏私人银行Brown Shipley国际私人银行部门客户总监。在此之前，Mun Gavin先生曾在Insinger De Beaufort、瑞士信贷、The Vanol Group、Swiss Bank Corporation Investment Banking Ltd.、Bankers Trust International Limited、Dr. Jonathan Beare家族办公室以及Goldby、Compton和Mackelvie Durban担任多个职务。Mun Gavin先生在纳塔尔大学获得了会计理论证书。
David C. Mun Gavin was appointed to Gt Biopharma, Inc.'s Board of Directors on June 10, 2025. Mr. Mun Gavin has served as the Client Director, International Private Banking Division, of Brown Shipley, a Quintet private bank, since October 2018. Prior to this, Mr. Mun Gavin served in various roles at Insinger De Beaufort, Credit Suisse, The Vanol Group, Swiss Bank Corporation Investment Banking Ltd., Bankers Trust International Limited, the Dr. Jonathan Beare Family Office, and Goldby, Compton and Mackelvie Durban. Mr. Mun Gavin earned a certificate in the theory of accountancy at University of Natal. - David C. Mun Gavin于2025年6月10日被任命为GT Biopharma, Inc.董事会成员。Mun Gavin先生自2018年10月起担任五重奏私人银行Brown Shipley国际私人银行部门客户总监。在此之前，Mun Gavin先生曾在Insinger De Beaufort、瑞士信贷、The Vanol Group、Swiss Bank Corporation Investment Banking Ltd.、Bankers Trust International Limited、Dr. Jonathan Beare家族办公室以及Goldby、Compton和Mackelvie Durban担任多个职务。Mun Gavin先生在纳塔尔大学获得了会计理论证书。
- David C. Mun Gavin was appointed to Gt Biopharma, Inc.'s Board of Directors on June 10, 2025. Mr. Mun Gavin has served as the Client Director, International Private Banking Division, of Brown Shipley, a Quintet private bank, since October 2018. Prior to this, Mr. Mun Gavin served in various roles at Insinger De Beaufort, Credit Suisse, The Vanol Group, Swiss Bank Corporation Investment Banking Ltd., Bankers Trust International Limited, the Dr. Jonathan Beare Family Office, and Goldby, Compton and Mackelvie Durban. Mr. Mun Gavin earned a certificate in the theory of accountancy at University of Natal.
- Hilary Kramer
-
Hilary Kramer于2025年5月7日被任命为公司董事会成员。自2006年以来，克莱默女士一直担任Greentech Research LLC的首席执行官、总裁和首席投资官，该公司是一家专注于替代能源和清洁技术的全球基金。在此之前，她曾在摩根士丹利和雷曼兄弟分别担任分析师和投资银行家。克莱默此前曾担任Ibero-American Media Partners II Ltd.的联席主管和董事，该公司是一家由Hicks，Muse，Tate & Furst共同拥有的价值10亿美元的私募股权基金。克莱默女士曾担任多家上市和私营公司的董事，包括INX Digital Company、RSL Communications，Inc.、El Sitio Inc.、Deltathree Inc.和Direct TV Latin America。她还咨询过家族办公室和机构，如Montgomery Asset Management、Freddie Mac，以及从拉丁美洲到中东的福布斯全球亿万富豪榜单上的家族。克莱默女士撰写了未来主义者和投资通讯GameChangers，并在140个市场的Salem Network上举办了一个全国性的联合投资广播节目。她著有《Ahead of the Curve》（Simon & Schuster 2007）和《小股票大利润小书》（Wiley 2012）和《Game Changing Investing》（Regnery 2020）。克莱默女士是《华尔街日报》女性商界的创始成员。克莱默女士拥有宾夕法尼亚大学沃顿商学院MBA学位和韦尔斯利学院荣誉学士学位。
Hilary Kramer was appointed to Gt Biopharma, Inc.'s Board of Directors on May 7, 2025. Ms. Kramer has served as the Chief Executive Officer, President and Chief Investment Officer of Greentech Research LLC, a global fund specializing in alternative energies and clean technologies, since 2006. Prior to this, she served as an analyst and investment banker at each of Morgan Stanley and Lehman Brothers. Ms. Kramer previously served as the co head and a director of Ibero American Media Partners II Ltd., a $1.0 billion private equity fund jointly owned by Hicks, Muse, Tate & Furst. Ms. Kramer has served as a director of multiple publicly traded and privately owned companies, including RSL Communications, Inc., El Sitio Inc., Deltathree Inc. and Direct TV Latin America. Ms. Kramer has served as a director of INX Digital Company, a Gibraltar based firm that specializes in digital asset trading and blockchain technology, since January 2023. She has also consulted with family offices and institutions, such as Montgomery Asset Management, Freddie Mac, and families on the Forbes list of global billionaires ranging from Latin America to the Middle East. Ms. Kramer authors the futurist investment newsletter, GameChangers, and has a nationally syndicated investment radio show on the Salem Network in 140 markets. She is the author of Ahead of the Curve (Simon & Schuster 2007) and The Little Book of Big Profits from Small Stocks (Wiley 2012) and Game Changing Investing (Regnery 2020). Ms. Kramer was a founding member of the Wall Street Journal Women in Business. Ms. Kramer holds an MBA from the Wharton School of the University of Pennsylvania and a BA with honors from Wellesley College. - Hilary Kramer于2025年5月7日被任命为公司董事会成员。自2006年以来，克莱默女士一直担任Greentech Research LLC的首席执行官、总裁和首席投资官，该公司是一家专注于替代能源和清洁技术的全球基金。在此之前，她曾在摩根士丹利和雷曼兄弟分别担任分析师和投资银行家。克莱默此前曾担任Ibero-American Media Partners II Ltd.的联席主管和董事，该公司是一家由Hicks，Muse，Tate & Furst共同拥有的价值10亿美元的私募股权基金。克莱默女士曾担任多家上市和私营公司的董事，包括INX Digital Company、RSL Communications，Inc.、El Sitio Inc.、Deltathree Inc.和Direct TV Latin America。她还咨询过家族办公室和机构，如Montgomery Asset Management、Freddie Mac，以及从拉丁美洲到中东的福布斯全球亿万富豪榜单上的家族。克莱默女士撰写了未来主义者和投资通讯GameChangers，并在140个市场的Salem Network上举办了一个全国性的联合投资广播节目。她著有《Ahead of the Curve》（Simon & Schuster 2007）和《小股票大利润小书》（Wiley 2012）和《Game Changing Investing》（Regnery 2020）。克莱默女士是《华尔街日报》女性商界的创始成员。克莱默女士拥有宾夕法尼亚大学沃顿商学院MBA学位和韦尔斯利学院荣誉学士学位。
- Hilary Kramer was appointed to Gt Biopharma, Inc.'s Board of Directors on May 7, 2025. Ms. Kramer has served as the Chief Executive Officer, President and Chief Investment Officer of Greentech Research LLC, a global fund specializing in alternative energies and clean technologies, since 2006. Prior to this, she served as an analyst and investment banker at each of Morgan Stanley and Lehman Brothers. Ms. Kramer previously served as the co head and a director of Ibero American Media Partners II Ltd., a $1.0 billion private equity fund jointly owned by Hicks, Muse, Tate & Furst. Ms. Kramer has served as a director of multiple publicly traded and privately owned companies, including RSL Communications, Inc., El Sitio Inc., Deltathree Inc. and Direct TV Latin America. Ms. Kramer has served as a director of INX Digital Company, a Gibraltar based firm that specializes in digital asset trading and blockchain technology, since January 2023. She has also consulted with family offices and institutions, such as Montgomery Asset Management, Freddie Mac, and families on the Forbes list of global billionaires ranging from Latin America to the Middle East. Ms. Kramer authors the futurist investment newsletter, GameChangers, and has a nationally syndicated investment radio show on the Salem Network in 140 markets. She is the author of Ahead of the Curve (Simon & Schuster 2007) and The Little Book of Big Profits from Small Stocks (Wiley 2012) and Game Changing Investing (Regnery 2020). Ms. Kramer was a founding member of the Wall Street Journal Women in Business. Ms. Kramer holds an MBA from the Wharton School of the University of Pennsylvania and a BA with honors from Wellesley College.
- Charles J. Casamento
-
Charles J. Casamento，于2017年3月被任命为董事会成员。2007年以来，Casamento先生一直担任The Sage Group（一家医疗保健咨询集团）的执行董事和负责人。此前，从2004年10月到2007年4月，他担任Osteologix（一家初创公司，他监督上市）的总裁兼首席执行官。从1999年到2004年，他是Questcor Pharmaceuticals的创始人，担任总裁、首席执行官和主席。在他任职Questcor期间，公司收购了Acthar，这款产品的销售额最终超过了10亿美元。他也曾担任RiboGene Inc.的总裁、首席执行官和主席，直到1999年RiboGene与另一家公司合并形成Questcor。他也是Indevus（前身为Interneuron Pharmaceuticals）的联合创始人、总裁兼首席执行官，并在Genzyme Corporation担任高级管理职位，在那里他曾担任美国医院供应高级副总裁，在那里他曾担任重症护理部门、Johnson & Johnson、hoffman - laroche和Sandoz的业务发展副总裁。他目前担任Relmada Therapeutics （OTCQB： RLMD）的董事会主席，Eton Pharmaceuticals （Nasdaq： Eton）的董事会成员，PaxMedica, Inc. （Nasdaq： PXMD）的董事会成员，此前担任Catholic Medical Missions Board（大型非营利性国际组织）的董事和副主席。他持有Fordham University的药学学士学位和Iona College的工商管理硕士学位。
Charles J. Casamento was appointed to Gt Biopharma, Inc.'s Board of Directors on May 1, 2023. Mr. Casamento is currently executive director and principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and chief executive officer of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. Mr. Casamento was founder of, and from 1999 through 2004, served as chairman of the board, president and chief executive officer, of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt Pharmaceuticals. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann LaRoche, Inc. and Sandoz Inc. (now Novartis). Mr. Casamento also serves on the board of directors of the following Nasdaq listed companies: Eton Pharmaceuticals, Inc., PaxMedica, Inc., First Wave Biopharma, Inc. and Relmada Therapeutics, Inc. During his career he has served on the boards of fourteen biotech/pharma companies and has also been a director and vice chairman of The Catholic Medical Missions Board, a large not for profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor's degree in Pharmacy from Fordham University and an MBA from Iona University and was previously licensed to practice pharmacy in the states of New York and New Jersey. - Charles J. Casamento，于2017年3月被任命为董事会成员。2007年以来，Casamento先生一直担任The Sage Group（一家医疗保健咨询集团）的执行董事和负责人。此前，从2004年10月到2007年4月，他担任Osteologix（一家初创公司，他监督上市）的总裁兼首席执行官。从1999年到2004年，他是Questcor Pharmaceuticals的创始人，担任总裁、首席执行官和主席。在他任职Questcor期间，公司收购了Acthar，这款产品的销售额最终超过了10亿美元。他也曾担任RiboGene Inc.的总裁、首席执行官和主席，直到1999年RiboGene与另一家公司合并形成Questcor。他也是Indevus（前身为Interneuron Pharmaceuticals）的联合创始人、总裁兼首席执行官，并在Genzyme Corporation担任高级管理职位，在那里他曾担任美国医院供应高级副总裁，在那里他曾担任重症护理部门、Johnson & Johnson、hoffman - laroche和Sandoz的业务发展副总裁。他目前担任Relmada Therapeutics （OTCQB： RLMD）的董事会主席，Eton Pharmaceuticals （Nasdaq： Eton）的董事会成员，PaxMedica, Inc. （Nasdaq： PXMD）的董事会成员，此前担任Catholic Medical Missions Board（大型非营利性国际组织）的董事和副主席。他持有Fordham University的药学学士学位和Iona College的工商管理硕士学位。
- Charles J. Casamento was appointed to Gt Biopharma, Inc.'s Board of Directors on May 1, 2023. Mr. Casamento is currently executive director and principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and chief executive officer of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. Mr. Casamento was founder of, and from 1999 through 2004, served as chairman of the board, president and chief executive officer, of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt Pharmaceuticals. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann LaRoche, Inc. and Sandoz Inc. (now Novartis). Mr. Casamento also serves on the board of directors of the following Nasdaq listed companies: Eton Pharmaceuticals, Inc., PaxMedica, Inc., First Wave Biopharma, Inc. and Relmada Therapeutics, Inc. During his career he has served on the boards of fourteen biotech/pharma companies and has also been a director and vice chairman of The Catholic Medical Missions Board, a large not for profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor's degree in Pharmacy from Fordham University and an MBA from Iona University and was previously licensed to practice pharmacy in the states of New York and New Jersey.
高管简历
中英对照 | 中文 | 英文- Michael Breen
Michael Breen自2017年3月起担任公司董事。Breen先生是一名英国合格的律师，曾担任Bank Insinger de Beaufort N.V.体育和娱乐部门的常务董事，这是一家财富管理机构，也是法国巴黎银行集团（BNP Paribas Group）的一部分，后者是世界上最大的银行之一。他曾担任Clyde&Co律师事务所的股权合伙人，在那里他专注于体育和娱乐法的所有方面。Breen先生还在基于事件的娱乐方面拥有丰富的经验，曾负责与世界著名的英国音乐奖（Brit Awards）相关的法律文件。Breen先生拥有威尔士大学学院（University College of Wales，Aberystwyth）法学荣誉法学学士学位。
Michael Breen was appointed to Gt Biopharma, Inc.'s Board of Directors on January 13, 2021, was appointed Executive Chairman of the Board of Directors on November 8, 2021 and was appointed as Gt Biopharma, Inc.'s Chief Executive Officer on April 29, 2025 for a two year term. Mr. Breen served as Gt Biopharma, Inc.'s Interim Chief Executive Officer from March 2, 2022 to April 29, 2025. Prior to joining Gt Biopharma, Inc.'s company, Mr. Breen served as a senior partner in the global law firm of Clyde & Co., specializing in all aspects of corporate law, including mergers and acquisitions and fund management regulatory issues, which included advising clients in the biotechnology and health sciences sectors. Prior to joining Clyde & Co., Mr. Breen served as a senior partner and managing partner in the London law firm of Edward Lewis. Prior to his time at Edward Lewis, he was also a partner at Robert Gore & Company. Between 2002 and 2005, Mr. Breen was managing director and a shareholder of the Sports and Entertainment Division of Insinger de Beaufort Bank, a Dutch private banking, asset management and trust group listed on the Luxembourg stock exchange. From 2001 to 2007 Mr. Breen also served as a non executive director and co owner of Damon Hill Holdings Limited, a multi franchise motor dealer group. Mr. Breen also serves as a director of a Cayman Islands fund, Bristol Investment Fund, Limited. Mr. Breen is also a non executive director and co owner of Colorsport Images Limited, a sports photographic agency and library. Mr. Breen is a U.K. qualified solicitor/attorney who holds an Honours LL.B. degree in law from the University College of Wales, Aberystwyth and qualified as a solicitor of the Supreme Court of Judicature of England and Wales in 1988. Mr. Breen is a former member of the International Bar Association, British Association for Sport and the Law, Law Society of England and Wales, and Holborn Law Society.- Michael Breen自2017年3月起担任公司董事。Breen先生是一名英国合格的律师，曾担任Bank Insinger de Beaufort N.V.体育和娱乐部门的常务董事，这是一家财富管理机构，也是法国巴黎银行集团（BNP Paribas Group）的一部分，后者是世界上最大的银行之一。他曾担任Clyde&Co律师事务所的股权合伙人，在那里他专注于体育和娱乐法的所有方面。Breen先生还在基于事件的娱乐方面拥有丰富的经验，曾负责与世界著名的英国音乐奖（Brit Awards）相关的法律文件。Breen先生拥有威尔士大学学院（University College of Wales，Aberystwyth）法学荣誉法学学士学位。
- Michael Breen was appointed to Gt Biopharma, Inc.'s Board of Directors on January 13, 2021, was appointed Executive Chairman of the Board of Directors on November 8, 2021 and was appointed as Gt Biopharma, Inc.'s Chief Executive Officer on April 29, 2025 for a two year term. Mr. Breen served as Gt Biopharma, Inc.'s Interim Chief Executive Officer from March 2, 2022 to April 29, 2025. Prior to joining Gt Biopharma, Inc.'s company, Mr. Breen served as a senior partner in the global law firm of Clyde & Co., specializing in all aspects of corporate law, including mergers and acquisitions and fund management regulatory issues, which included advising clients in the biotechnology and health sciences sectors. Prior to joining Clyde & Co., Mr. Breen served as a senior partner and managing partner in the London law firm of Edward Lewis. Prior to his time at Edward Lewis, he was also a partner at Robert Gore & Company. Between 2002 and 2005, Mr. Breen was managing director and a shareholder of the Sports and Entertainment Division of Insinger de Beaufort Bank, a Dutch private banking, asset management and trust group listed on the Luxembourg stock exchange. From 2001 to 2007 Mr. Breen also served as a non executive director and co owner of Damon Hill Holdings Limited, a multi franchise motor dealer group. Mr. Breen also serves as a director of a Cayman Islands fund, Bristol Investment Fund, Limited. Mr. Breen is also a non executive director and co owner of Colorsport Images Limited, a sports photographic agency and library. Mr. Breen is a U.K. qualified solicitor/attorney who holds an Honours LL.B. degree in law from the University College of Wales, Aberystwyth and qualified as a solicitor of the Supreme Court of Judicature of England and Wales in 1988. Mr. Breen is a former member of the International Bar Association, British Association for Sport and the Law, Law Society of England and Wales, and Holborn Law Society.
- Alan Urban
Alan Urban此前曾于2022年6月至2023年5月担任公司董事会成员；于2023年3月至2023年7月担任金融科技公司SRAX，Inc.（OTC：SRAX）的首席财务官；于2021年11月至2023年3月担任加密货币挖矿公司Creek Road Miners，Inc.（原OTC：CRKR）的首席财务官；于2011年10月至2021年10月担任科学、技术和医疗信息领域的SaaS和内容提供商Research Solutions, Inc.，Inc.（NASDAQ：RSSS）的TERM3首席财务官及秘书。在其职业生涯的早期，Urban先生曾在互联网营销公司ReachLocal，Inc.（NASDAQ：RLOC）担任首席财务官兼财务和会计高级副总裁；在科学、技术和医疗信息领域的内容提供商Infotrieve，Inc.担任财务副总裁兼财务主管。1998年至今任注册会计师（现不任职）。Urban先生在北岭的加州州立大学获得了商学学士学位，主修会计理论和实践。
Alan Urban has previously served as a member of the Board of Directors of the Company from June 2022 to May 2023; as Chief Financial Officer for SRAX, Inc. (OTC: SRAX), a financial technology company, from March 2023 to July 2023; as Chief Financial Officer for Creek Road Miners, Inc. (formerly OTC: CRKR), a cryptocurrency mining company, from November 2021 to March 2023; and as Chief Financial Officer and Secretary for Research Solutions, Inc. (NASDAQ: RSSS), a SaaS and content provider in the scientific, technical and medical information space, from October 2011 to October 2021. Earlier in his career, Mr. Urban served as Chief Financial Officer and Senior Vice President of Finance and Accounting for ReachLocal, Inc. (NASDAQ: RLOC), an internet marketing company; and as Vice President of Finance and Treasurer for Infotrieve, Inc., a content provider in the scientific, technical and medical information space. He has been a Certified Public Accountant (currently inactive) since 1998. Mr. Urban received a B.S. in Business, with a concentration in Accounting Theory and Practice, from California State University, Northridge.- Alan Urban此前曾于2022年6月至2023年5月担任公司董事会成员；于2023年3月至2023年7月担任金融科技公司SRAX，Inc.（OTC：SRAX）的首席财务官；于2021年11月至2023年3月担任加密货币挖矿公司Creek Road Miners，Inc.（原OTC：CRKR）的首席财务官；于2011年10月至2021年10月担任科学、技术和医疗信息领域的SaaS和内容提供商Research Solutions, Inc.，Inc.（NASDAQ：RSSS）的TERM3首席财务官及秘书。在其职业生涯的早期，Urban先生曾在互联网营销公司ReachLocal，Inc.（NASDAQ：RLOC）担任首席财务官兼财务和会计高级副总裁；在科学、技术和医疗信息领域的内容提供商Infotrieve，Inc.担任财务副总裁兼财务主管。1998年至今任注册会计师（现不任职）。Urban先生在北岭的加州州立大学获得了商学学士学位，主修会计理论和实践。
- Alan Urban has previously served as a member of the Board of Directors of the Company from June 2022 to May 2023; as Chief Financial Officer for SRAX, Inc. (OTC: SRAX), a financial technology company, from March 2023 to July 2023; as Chief Financial Officer for Creek Road Miners, Inc. (formerly OTC: CRKR), a cryptocurrency mining company, from November 2021 to March 2023; and as Chief Financial Officer and Secretary for Research Solutions, Inc. (NASDAQ: RSSS), a SaaS and content provider in the scientific, technical and medical information space, from October 2011 to October 2021. Earlier in his career, Mr. Urban served as Chief Financial Officer and Senior Vice President of Finance and Accounting for ReachLocal, Inc. (NASDAQ: RLOC), an internet marketing company; and as Vice President of Finance and Treasurer for Infotrieve, Inc., a content provider in the scientific, technical and medical information space. He has been a Certified Public Accountant (currently inactive) since 1998. Mr. Urban received a B.S. in Business, with a concentration in Accounting Theory and Practice, from California State University, Northridge.